"Buntanetap (previously known as ANVS401 or Posiphen) is our lead compound. It is a translational inhibitor of neurotoxic aggregating proteins (TINAPs). Different from monoclonal antibody therapies, buntanetap is an orally available small molecule, and its unique mechanism of action allows it to inhibit multiple neurotoxic proteins at once. Recent research has shown that multiple neurotoxic proteins are at play in all neurodegenerative diseases."
"Buntanetap, thus, offers a transformative and superior mechanism to treat neurodegenerative disorders. It’s being developed for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions such as Alzheimer’s in Down syndrome."
"Cheng Fang, PhD, Annovis Bio, Berwyn, PA, explains the unique mechanism of action of investigational small molecule, buntanetap. Buntanetap is an orally available agent, acting as a translational inhibitor of neurotoxic aggregating proteins. It acts on the iron response element in the 5′-untranslated region of mRNA that is preserved among neurotoxic aggregating proteins. Buntanetap increases the affinity of iron regulatory protein 1 (IRP1) to IRE, preventing association with the ribosome and thus, inhibiting translation. Buntanetap has been shown to inhibit the translation of multiple neurotoxic proteins such as amyloid precursor protein, tau and alpha-synuclein. In preclinical models, buntanetap was able to restore axonal transport, lower inflammation and protect against cell death. Its mechanism of action makes it a promising candidate in several neurodegenerative diseases where toxic protein aggregation and accumulation is at play. It is currently being developed for Alzheimer’s disease (AD) and Parkinson’s disease (PD), showing improvement in cognition in patients with AD and motor function in patients with PD in Phase II studies. This interview took place at the Alzheimer's Association International Conference (AAIC) 2022 in San Diego, CA."
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Fasting. I recently have gone to OMAD.
Annovis Bio Announces Approval for EU Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
Buntanetape updates
Excess iron in the brain contributes to neurodegeneration. How do we reduce this? Iron chelator? Oxalates? 
